These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38700511)
1. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies. Sepp A; Muliaditan M MAbs; 2024; 16(1):2324485. PubMed ID: 38700511 [TBL] [Abstract][Full Text] [Related]
2. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Glassman PM; Balthasar JP J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311 [TBL] [Abstract][Full Text] [Related]
3. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. Cao Y; Jusko WJ J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917 [TBL] [Abstract][Full Text] [Related]
4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Shah DK; Betts AM J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465 [TBL] [Abstract][Full Text] [Related]
6. Target-mediated drug disposition model for drugs that bind to more than one target. Gibiansky L; Gibiansky E J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044 [TBL] [Abstract][Full Text] [Related]
7. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546 [TBL] [Abstract][Full Text] [Related]
8. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition. Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865 [TBL] [Abstract][Full Text] [Related]
9. Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies. Muliaditan M; Sepp A Clin Transl Sci; 2022 Jul; 15(7):1634-1643. PubMed ID: 35445800 [TBL] [Abstract][Full Text] [Related]
10. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918 [TBL] [Abstract][Full Text] [Related]
11. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Glassman PM; Chen Y; Balthasar JP J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301 [TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation. Haraya K; Tsutsui H; Komori Y; Tachibana T Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631335 [TBL] [Abstract][Full Text] [Related]
13. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab. Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343 [TBL] [Abstract][Full Text] [Related]
14. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Ben-Kasus T; Schechter B; Lavi S; Yarden Y; Sela M Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3294-9. PubMed ID: 19218427 [TBL] [Abstract][Full Text] [Related]
15. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Glassman PM; Balthasar JP Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890 [TBL] [Abstract][Full Text] [Related]
16. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product. Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073 [TBL] [Abstract][Full Text] [Related]
17. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues. Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351 [TBL] [Abstract][Full Text] [Related]
18. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. Grimm HP J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):407-20. PubMed ID: 19728050 [TBL] [Abstract][Full Text] [Related]